ArticleJournal of the colleges of medicine of South Africa2024
Bullous pemphigoid and its association with neurological diseases.
Article in Journal of the colleges of medicine of South Africa, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bullous Pemphigoid (BP) is the most common immunobullous skin disease. Methods: This was a descriptive cross-sectional study of electronic health records data at a specialist dermatology clinic at Tygerberg Hospital in the Western Cape. Patients presenting during a predefined 5-year period with a clinicopathologic diagnosis of BP were included. Results: The final sample comprised 54 cases of BP. The median age at diagnosis was 71.0 years, and 64.8% were female. Eighty per cent had at least one chronic medical condition at the time of BP diagnosis. The most common comorbidities were hypertension (63.0%), diabetes mellitus (33.3%) and strokes (24.1%). Twenty-eight per cent had been diagnosed with at least one neurological comorbidity at the time of BP diagnosis. Patients experienced a median delay of 45 days (interquartile range: 21.0-90.0 days) between onset of symptoms and presentation to dermatology. Conclusion: This is the first study reporting co-morbidities in patients with BP in sub-Saharan Africa. Despite the high burden of disease due to physical injury in the study setting, no patients with BP had a history of traumatic brain injury. This suggests the possibility that the association between BP and neurologic disorders is limited to stroke, epilepsy, and neurodegenerative diseases. Future prospective cohort studies are indicated to further investigate the results of this study. Contribution: To describe neurologic and other comorbidities in patients presenting with BP at a tertiary hospital in South Africa. This research in South Africa, a lower-middle-income country, seeks to address knowledge gaps, utilize data, and advance the field of dermatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.